NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis $6.22 +0.18 (+2.98%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.07▼$6.4550-Day Range$4.93▼$6.5352-Week Range$2.09▼$8.17Volume86,652 shsAverage Volume162,812 shsMarket Capitalization$166.26 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Syros Pharmaceuticals alerts: Email Address Syros Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside125.1% Upside$14.00 Price TargetShort InterestBearish6.39% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.63Based on 3 Articles This WeekInsider TradingSelling Shares$178,365 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.19) to ($2.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector184th out of 936 stocksPharmaceutical Preparations Industry77th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Syros Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.39% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 3.05%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 64.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.88. Previous Next 2.6 News and Social Media Coverage News SentimentSyros Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Syros Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for SYRS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $178,365.00 in company stock.Percentage Held by Insiders12.26% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Syros Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($3.19) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 7.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syros Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Syros Pharmaceuticals Stock (NASDAQ:SYRS)Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Read More SYRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRS Stock News HeadlinesJuly 4, 2024 | insidertrades.comRichard A. Young Sells 34,837 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) StockJuly 20, 2024 | finance.yahoo.comSyros Pharmaceuticals Inc (0S90.SG)July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 13, 2024 | businesswire.comSyros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene OverexpressionMay 16, 2024 | markets.businessinsider.comOptimistic Outlook for Syros Pharmaceuticals with Promising Clinical Trials and Regulatory AdvancementsMay 15, 2024 | markets.businessinsider.comHere's what Wall Street expects from Syros Pharmaceuticals's earningsMay 15, 2024 | finance.yahoo.comSyros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comQ1 2024 Syros Pharmaceuticals Inc Earnings CallJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 14, 2024 | msn.comSyros Pharmaceuticals GAAP EPS of -$0.10 beats by $0.77May 14, 2024 | msn.comSYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | businesswire.comSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 7, 2024 | businesswire.comSyros to Participate in Upcoming Investor ConferencesMay 7, 2024 | businesswire.comSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024April 10, 2024 | marketwatch.comSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for TamibaroteneApril 9, 2024 | msn.comSyros jumps on FDA fast track tag for leukemia drugApril 9, 2024 | markets.businessinsider.comFast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid LeukemiaApril 9, 2024 | businesswire.comSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionSee More Headlines Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+124.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-164,570,000.00 Net Margins-1,656.34% Pretax Margin-2,069.51% Return on Equity-395.36% Return on Assets-88.41% Debt Debt-to-Equity Ratio1.97 Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual Sales$9.94 million Price / Sales16.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book7.90Miscellaneous Outstanding Shares26,730,000Free Float23,451,000Market Cap$166.80 million OptionableOptionable Beta1.53 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Conley Chee (Age 54)CEO, President & Director Comp: $672.24kDr. Richard A. Young Ph.D. (Age 70)Scientific Founder, Member of Scientific Advisory Board & Director Comp: $51.75kMr. Jason Haas (Age 56)Chief Financial Officer Comp: $672.22kDr. David A. Roth M.D. (Age 61)Chief Medical Officer Comp: $715.73kDr. James E. Bradner M.D. (Age 52)Founder Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardMs. Karen Hunady M.S.Director of Corporate Communications & Investor RelationsMr. Gerald E. Quirk Esq. (Age 56)J.D., Chief Legal Officer & Head of Business Development Comp: $127.07kMs. Lisa RobertsVice President of Human ResourcesMs. Kristin Stephens (Age 51)Chief Development Officer More ExecutivesKey CompetitorsCue BiopharmaNASDAQ:CUEProgenics PharmaceuticalsNASDAQ:PGNXSIGA TechnologiesNASDAQ:SIGAMineralys TherapeuticsNASDAQ:MLYSSavaraNASDAQ:SVRAView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 154,126 shares on 7/18/2024Ownership: 0.059%Richard A YoungSold 34,837 sharesTotal: $178,365.44 ($5.12/share)Opaleye Management Inc.Bought 428,175 shares on 5/29/2024Ownership: 2.947%Virtu Financial LLCBought 12,030 shares on 5/20/2024Ownership: 0.045%Kennedy Capital Management LLCBought 404,914 shares on 5/16/2024Ownership: 1.515%View All Insider TransactionsView All Institutional Transactions SYRS Stock Analysis - Frequently Asked Questions How have SYRS shares performed this year? Syros Pharmaceuticals' stock was trading at $7.79 on January 1st, 2024. Since then, SYRS shares have decreased by 20.2% and is now trading at $6.22. View the best growth stocks for 2024 here. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative trailing twelve-month return on equity of 395.36%. When did Syros Pharmaceuticals' stock split? Syros Pharmaceuticals's stock reverse split before market open on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Syros Pharmaceuticals IPO? Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.06%). Insiders that own company stock include Timothy Tyson, David Roth, Richard A Young and Eric R Olson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV) and Amarin (AMRN). This page (NASDAQ:SYRS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
